RLY-2608

SKU: orb1943500

Description

RLY-2608 is a potent and selective inhibitor of mutant PI3Kα. It demonstrates anti-tumor activity in PIK3CA-mutant xenograft models, supporting its use in preclinical oncology research for studying PI3K pathway-driven cancers both in vitro and in vivo.

Research Area

Signal Transduction

Key Properties

• CAS Number: 2733573-94-7
• MW: 608.91
• Purity: 99.87% (May vary between batches)
• Formula: C₂₉H₁₄ClF₅N₆O₂
• SMILES: N(C(=O)C1=CC(C(F)(F)F)=CC(F)=C1)C2=C3[C@@H](NC(=O)C3=CC(=C2)C4=C(C#N)N5C(C=C4)=NC=N5)C6=C(Cl)C=CC(F)=C6
• Target: PI3K
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.21 mM);DMSO:80 mg/mL (131.38 mM)

Bioactivity

• Target IC50:
  PI3Kα:4 nM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RLY 2608, RLY2608, PI3Kα, Zovegalisib

Compound Identifiers

PubChem CID

166822065